deepCDR Biologics AG

Antibody discovery enabled by deep learning.

We harness the power of machine learning to move beyond experimental screening found in traditional therapeutic antibody discovery and engineering processes. To achieve this, we combine three state-of-the-art techniques in protein engineering: gene editing, deep sequencing, and deep learning. With our proprietary mammalian system and drug discovery workflow, we generate thousands of optimized lead candidates ready for preclinical studies at a fraction of the time and cost.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Website

IMD Startup Competition

The IMD Startup Competition provides an unique opportunity for regional technology startups to benefit from the help and insights of a team of dedicated, experienced IMD participants from the MBA and the Executive MBA programs.

Website

Venture Leaders Biotech

deepCDR Biologics AG

Antibody discovery enabled by deep learning.
Acquired by:
Alloy Therapeutics

Headquarter:
Basel

Foundation Date:
March 2019

Technology:

  • Biotech

Sectors:

  • Antibodies
  • Bioinformatics
  • Cancer
  • Drug development platforms
  • Drug discovery
  • Machine Learning / AI
  • Tackle COVID-19

Support received

  • Support venture leaders
  • Support venturekick